Key facts
- This page summarizes Michael John Dawson's Form 4 filing for PALISADE BIO, INC. (PALI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Mar 2022, 08:31.
Michael John Dawson - 29 Mar 2022 Form 4 Insider Report for PALISADE BIO, INC. (PALI)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PALI
- Reported as of
- 29 Mar 2022
- Net transaction value
- +$17,092
- SEC form
- 4
- Accepted by SEC
- 31 Mar 2022, 08:31:44 UTC
- Prior SEC filing
- 22 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ JD Finley, Attorney-in-Fact for Michael Dawson
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael John Dawson filed Form 4 for PALISADE BIO, INC. (PALI) on 31 Mar 2022.
Change
- Previous filing in this sequence was filed on 22 Feb 2022.
- Current net transaction value: +$17,092.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PALI
transaction
Common Stock
Purchase
- Transaction value
- $17,092
- Shares
- +15,000
- Change %
- Price
- $1.14
- Shares after
- 15,000
- Date
- 29 Mar 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.